A tumor-binding antibody with cross-reactivity to viral antigens
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-03975-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Michael J Campa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Duke University School of Medicine, Durham, NC, 27710, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antigens, Viral, Autoantibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: We previously identified in non-small cell lung cancer (NSCLC) patients an autoantibody to complement factor H (CFH) that is associated with non-metastatic disease and longer time to progression in patients with stage I disease. A recombinant human antibody, GT103, was cloned from single B cells isolated from patients with the autoantibody. GT103 inhibits tumor growth and establishes an antitumor microenvironment. The anti-CFH autoantibody and GT103 recognize the epitope PIDNGDIT within the SCR19 domain of CFH. Here, we asked if this autoantibody could have originally arisen as a humoral response to a similar epitope in a viral protein from a prior infection. METHODS: Homologous viral peptides with high sequence identity to the core PIDNGDIT epitope sequence were identified and synthesized. NSCLC patient plasma containing anti-CFH autoantibodies were assayed by ELISA against these peptides. GT103 was assayed on a 4345-peptide pathogen microarray. RESULTS: Epitopes similar to the GT103 epitope are present in several viruses, including human metapneumovirus-1 (HMPV-1) that contains a sequence within attachment glycoprotein G that differs by one amino acid. Anti-CFH autoantibodies in NSCLC patient plasma weakly bound to an HMPV-1 peptide containing the epitope. GT103 cross-reacted with multiple viral epitopes on a peptide microarray, with the top hits being peptides in the human endogenous retrovirus-K polymerase (HERV-K pol) protein and measles hemagglutinin glycoprotein. GT103 bound the viral HMPV-1, HERV-K pol, and measles epitope peptides but with lower affinity compared to the GT103 epitope peptide. CONCLUSION: These findings suggest that memory B cells against a viral target could have affinity matured to produce an antibody that recognizes a similar epitope on tumor cells and exhibits antitumor properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Duke University School of Medicine, Durham, NC, 27710, USA.
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
- Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
- Department of Radiology, Duke University School of Medicine, Durham, NC, 27710, USA. patz0002@mc.duke.edu.
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, 27710, USA. patz0002@mc.duke.edu.
Zitieren
APA
Campa, M. J., Gottlin, E. B., Wiehe, K., & Patz, E. F. (2025). A tumor-binding antibody with cross-reactivity to viral antigens. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03975-8
Vancouver
Campa MJ, Gottlin EB, Wiehe K, Patz EF. A tumor-binding antibody with cross-reactivity to viral antigens. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03975-8
BibTeX
@article{Campa2025,
author = {Campa, Michael J and Gottlin, Elizabeth B and Wiehe, Kevin and Patz, Edward F},
title = {A tumor-binding antibody with cross-reactivity to viral antigens},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-03975-8}
}
EUVIMED